Dexmedetomidine as an Adjuvant to Greater Auricular Nerve Block in Middle Ear Surgeries

Condition(s) studied

Investigational drug(s) / intervention(s)

Bupivacaine: 2 ml of bupivacaine 0.25% injected around the greater auricular nerve under ultrasound guidance before induction of general anesthesia.

Dexmedetomidine: 1 ml of dexmedetomidine 0.5 µg/kg added to bupivacaine in the greater auricular nerve block.

Normal saline: 1 ml of normal saline 0.9% added to 2 ml bupivacaine 0.25% in the greater auricular nerve block.

Ultrasound-guided greater auricular nerve block: Ultrasound-guided block of the greater auricular nerve performed before induction of general anesthesia in both groups.

Study summary

This randomized, double-blind, controlled study will evaluate whether adding dexmedetomidine to bupivacaine in an ultrasound-guided greater auricular nerve block prolongs pain relief after middle ear surgery. Adults undergoing elective middle ear surgery under general anesthesia will receive the block before induction, either with bupivacaine alone or with bupivacaine plus dexmedetomidine. The main outcome is how long pain relief lasts after the block. Other outcomes include pain scores, opioid use, emergence agitation, hemodynamic changes, and side effects.

Eligibility

Primary outcome measure(s)

• Duration of Analgesia — 24 hours after surgery
  Time from completion of the greater auricular nerve block until the patient's first request for rescue analgesia after surgery.

Trial sites (1)

More Minia University trials in Egypt

Other trials for the same condition